A tiny bubble of lipids, enzymes and DNA has done something biologists have chased for years: it carried out a full cycle of ...

BrainChild Bio advancing BCB-276 towards BLA submission with a single pivotal Phase 2 trial planned to commence in Q4 2025 SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical ...

Unlike accidental cell death, some cells can actively decide to die through a controlled process. This is called programmed ...

CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming next generation cell therapies, today announced a research and development collaboration with Mayo Clinic focused on ...

A new multiplex immunofluorescence workflow using standard laboratory equipment and open-source software enables detailed ...

Jonathan Kotula: We think there needs to be a systems-level approach to deal with complex diseases such as cancer. A lot of what has been done so far are reductionist approaches—one small molecule for ...

Through the collaboration, Applied StemCell is providing Syntax Bio with iPSC lines, including its GMP-compatible hypoimmune iPSC platform, which combines immune-evasion genome engineering with ...

One of ANSTO's advanced imaging instruments Dingo now delivers a rare fusion of simulation and radiobiology, becoming a launchpad for an innovative neutron therapy innovation. This unique scientific ...

Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Ajinomoto Health & Nutrition North America, Inc. (AHN), a leader in amino acid science and cell culture ...